• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy.
Authors: Hemati M, Haghiralsadat F, Yazdian F, Jafari F, Moradi A, Malekpour-Dehkordi Z Abstract The aim of this study was to optimize the cationic PEGylated niosome-containing anti-cancer drugs and siRNA to enhance the therapeutic response. Therefore, various surfactant-based (tween-60) vesicles of doxorubicin (DOX; a chemotherapeutic drug) and quercetin (QC; a chemosensitizer) were prepared. To load siRNA on niosomes, 1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) was used as a cationic lipid. The optimum formulation containing tween-60:cholesterol:DPPC:DOTAP:DSPE-PEG2000 at 49.5:5.5:15:25:5 demonstrated that ...
Source: Artificial Cells, Nanomedicine and Biotechnology - July 24, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Effects of chitosan nanoparticle-mediated BRAF siRNA interference on invasion and metastasis of gastric cancer cells
Artificial Cells, Nanomedicine, and Biotechnology, Ahead of Print.
Source: Artificial Cells, Blood Substitutes, and Biotechnology - March 22, 2015 Category: Biotechnology Tags: article Source Type: research

BST2 promotes cell proliferation, migration and induces NF- κB activation in gastric cancer.
CONCLUSION: BST2 possesses the oncogenic potential in GC by regulating the proliferation, apoptosis, and migratory ability of GC cells, thereby BST2 could be a potential therapeutic target for the treatment of GC. PMID: 29774441 [PubMed - as supplied by publisher]
Source: Biotechnology Letters - May 17, 2018 Category: Biotechnology Authors: Liu W, Cao Y, Guan Y, Zheng C Tags: Biotechnol Lett Source Type: research